DIFFUSE CORRELATION SPECTROSCOPY/STROKE: Noninvasive optical method promises personalized stroke treatment

May 19, 2014
A new optical method for continuous bedside monitoring of cerebral blood flow (CBF) incorporates a noninvasive probe placed on the surface of a patient's head to measure fluctuations in near-infrared (NIR) light that has traveled through the skull and into the brain, then back out to the tissue surface.

A new optical method for continuous bedside monitoring of cerebral blood flow (CBF) incorporates a noninvasive probe placed on the surface of a patient's head to measure fluctuations in near-infrared (NIR) light that has traveled through the skull and into the brain, then back out to the tissue surface. The representative device, designed at the University of Pennsylvania (Philadelphia, PA), has allowed researchers from Penn Medicine and the Department of Physics & Astronomy in Penn Arts and Sciences to make an important discovery that could improve treatment for stroke—a.k.a. cerebrovascular accident (CVA).

After suffering acute stroke, most hospital patients are kept flat for at least 24 hours to increase CBF in vulnerable brain regions surrounding the damage. Research using the new device shows that while a flat head of bed (HOB) did increase CBF in the damaged hemisphere for most stroke patients, a substantial minority (~25%) showed more CBF with their head elevated.

The NIR light fluctuations measured by the approach—caused by red blood cells moving through tissue—have been shown to accurately track CBF in underlying brain tissue. The novel technique, called diffuse correlation spectroscopy (DCS), has proven more sensitive for detecting CBF changes with HOB positioning than transcranial Doppler, which uses acoustic waves to quantify blood flow velocity of the large arteries supplying the brain.

"This study illustrates the potential of using advanced technology to make individualized treatment decisions in real time," said senior author John A. Detre, MD, professor of Neurology and Radiology in the Perelman School of Medicine at the university. Stroke is the leading cause of disability in industrialized nations and a leading cause of death.

The U.S. Patent Office has granted patent 8,082,015 to the University of Pennsylvania for the optical CBF technology. Besides application to neurological disorders, it is being tested in a number of other clinical populations in whom CBF changes are relevant.

1. C.G. Favilla et al., Stroke, 45, 1269–1274 (2014); doi:10.1161/strokeaha.113.004116.

Sponsored Recommendations

Request a free Micro 3D Printed sample part

April 11, 2024
The best way to understand the part quality we can achieve is by seeing it first-hand. Request a free 3D printed high-precision sample part.

How to Tune Servo Systems: The Basics

April 10, 2024
Learn how to tune a servo system using frequency-based tools to meet system specifications by watching our webinar!

Motion Scan and Data Collection Methods for Electro-Optic System Testing

April 10, 2024
Learn how different scanning patterns and approaches can be used in measuring an electro-optic sensor performance, by reading our whitepaper here!

How Precision Motion Systems are Shaping the Future of Semiconductor Manufacturing

March 28, 2024
This article highlights the pivotal role precision motion systems play in supporting the latest semiconductor manufacturing trends.

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!